Four things to know:
1. Second quarter sales grew 2.4 percent year-over-year. For the first half of 2023, sales were $625.5 million.
2. NuVasive saw a net income of $7.4 million in the second quarter.
3. Revenue was primarily driven by increased product adoption and increased surgical volumes in the U.S.
4. The company is maintaining its full-year growth projection of 6 percent to 8 percent revenue increases compared to 2022.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
